www.crucell.com
Crucell focuses on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide
Articles
-

17/09/2010
Crucell soars more than 50% after Johnson & Johnson makes $2.3 billion potential offer
Johnson & Johnson, through an affiliate, currently holds an approximate 17.9% stake in Crucell and has already submitted a statement to the SEC saying it plans to change its investment intent.
News
-
06/04/10
Crucell and GlaxoSmithKline to collaborate on second generation malaria vaccine candidate -
09/02/10
Biopharmaceutical company Crucell N.V. reports record 2009 revenues and profits
Recent Sector News
-

Dow suffers on Greece fears, Hewlett-Packard in focus
U.S. equity markets fell Wednesday afternoon on concerns that Greece could exit the euro as the region’s gather for an informal meeting.
-

Dow points lower ahead of eurozone meeting, Facebook, Dell in focus
U.S. equity markets looked set to open lower Wednesday morning ahead of a meeting of European Union leaders amid continued worries over the eurozone debt crisis.
-

Q1 gold demand underpinned by China, Central Banks and ETFs
Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
-

Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up
Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
-

Facebook boosts public offering by 25%
Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
-

Snipp plans ambitious growth as mobile marketing takes off
Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.
What do others think of Crucell
Investors interested in Crucell recently viewed
-
Eco Animal Health Group Plc (AIM: EAH) ECO Animal Health - applying science carefully to animal health markets -
Stirling Products (ASX: STI) Your wellbeing is our priority -
ReNeuron (AIM: RENE) Leading stem cell company targeting areas of significant unmet medical need -
iBio (AMEX: IBIO) Development and commercialization of novel plant-made products -
Medgenics (AIM: MEDG) Developing "Biopump" technology for the treatment of chronic diseases


















